(Q41675055)

6 October 2017

Helicobacter pylori and gastric cancer: what are the benefits of screening only for the CagA phenotype of H. pylori? (English)

1 reference

6 October 2017

0 references

Harris RA

1

1 reference

6 October 2017

Owens DK

series ordinal

2

1 reference

6 October 2017

Witherell H

series ordinal

3

1 reference

6 October 2017

Parsonnet J

series ordinal

4

1 reference

6 October 2017

1 June 1999

1 reference

6 October 2017

1 reference

6 October 2017

4

1 reference

6 October 2017

2

1 reference

6 October 2017

69-76

1 reference

Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii

6 October 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Helicobacter pylori infection and the risk of gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Seroprevalence of CagA-positive strains among Helicobacter pylori-infected, healthy young adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Intrastrain differences in Helicobacter pylori: a key question in mucosal damage?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Helicobacter pylori induced interleukin-8 expression in gastric epithelial cells is associated with CagA positive phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Risk for gastric cancer in people with CagA positive or CagA negative Helicobacter pylori infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Intragastric acidity as a predictor of the success of Helicobacter pylori eradication: a study in peptic ulcer patients with omeprazole and amoxicillin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Improvement of gastric inflammation and resolution of epithelial damage one year after eradication of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

The distinction between cost and charges

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Age-dependent increase of Campylobacter pylori antibodies in blood donors

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1523-5378.1999.98057.X

10.1046/J.1523-5378.1999.98057.X

21 January 2018

Identifiers

DOI

1 reference

6 October 2017

1 reference